BRPI0512040A - composição farmacêutica, método de modificação de receptores de célula de tumor, método de aperfeiçoar seletividade alvo de anticorpos, método de tratar cáncer, kit, uso de prolina - Google Patents
composição farmacêutica, método de modificação de receptores de célula de tumor, método de aperfeiçoar seletividade alvo de anticorpos, método de tratar cáncer, kit, uso de prolinaInfo
- Publication number
- BRPI0512040A BRPI0512040A BRPI0512040-3A BRPI0512040A BRPI0512040A BR PI0512040 A BRPI0512040 A BR PI0512040A BR PI0512040 A BRPI0512040 A BR PI0512040A BR PI0512040 A BRPI0512040 A BR PI0512040A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- proline
- treating cancer
- kit
- tumor cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
COMPOSIçãO FARMACêUTICA, MéTODO DE MODIFICAçãO DE RECEPTORES DE CéLULA DE TUMOR, MéTODO DE APERFEIçOAR SELETIVIDADE ALVO DE ANTICORPOS, MéTODO DE TRATAR CANCER, KIT, USO DE PROLINA A presente invenção refere-se a uma composição farmacêutica compreendendo prolina ou derivados de prolina ou seus sais, ésteres, isómeros, racematos, enanciómeros ou pró-drogas em conjunto com um ligante anticâncer, preferivelmente um anticorpo dirigido a um antigeno de tumor. A invenção também á dirigida ao uso de prolina ou derivados de prolina ou seus sais, ásteres, isómeros ou pró-drogas para a fabricação de uma composição farmacêutica para tratar câncer e a um método de tratamento de câncer mediante administração da composição.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57883204P | 2004-06-14 | 2004-06-14 | |
| PCT/EP2005/006184 WO2005120495A1 (en) | 2004-06-14 | 2005-06-07 | Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0512040A true BRPI0512040A (pt) | 2008-02-06 |
Family
ID=35064616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0512040-3A BRPI0512040A (pt) | 2004-06-14 | 2005-06-07 | composição farmacêutica, método de modificação de receptores de célula de tumor, método de aperfeiçoar seletividade alvo de anticorpos, método de tratar cáncer, kit, uso de prolina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7727530B2 (pt) |
| EP (1) | EP1765328B1 (pt) |
| JP (1) | JP2008502622A (pt) |
| KR (1) | KR20070026646A (pt) |
| CN (1) | CN1997365A (pt) |
| AT (1) | ATE534386T1 (pt) |
| AU (1) | AU2005251463A1 (pt) |
| BR (1) | BRPI0512040A (pt) |
| CA (1) | CA2568306A1 (pt) |
| MX (1) | MXPA06014731A (pt) |
| RU (1) | RU2007101074A (pt) |
| WO (1) | WO2005120495A1 (pt) |
| ZA (1) | ZA200700367B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY138883A (en) * | 2000-08-29 | 2009-08-28 | Government Of Malaysia As Represented By The Ministry Of Science Tehnology And Innovation Malaysia | Use of asiatic acid for treatment of cencer |
| JP2005518453A (ja) | 2002-02-25 | 2005-06-23 | ディフュージョン・ファーマシューティカルズ・エルエルシー | 二極性トランスカロテノイド塩およびそれらの使用 |
| US7759506B2 (en) | 2002-02-25 | 2010-07-20 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
| EP2540696B1 (en) | 2005-02-24 | 2020-01-01 | Diffusion Pharmaceuticals LLC | Trans carotenoids, formulation and uses |
| KR101570131B1 (ko) | 2007-04-13 | 2015-11-18 | 디퓨젼 파마슈티컬즈 엘엘씨 | 양극성 트랜스 카로티노이드의 말초혈관질환 치료와 예방을 위한 용도 |
| JP2011502125A (ja) | 2007-10-31 | 2011-01-20 | ディフュージョン・ファーマシューティカルズ・エルエルシー | 小分子拡散を促進する新しい種類の治療法 |
| EP2445339B1 (en) | 2009-06-22 | 2019-08-07 | Diffusion Pharmaceuticals LLC | Diffusion enhancing compound and its use with a thrombolytic |
| KR101894111B1 (ko) * | 2010-06-01 | 2018-08-31 | 메타노믹스 헬스 게엠베하 | 대상체에서 췌장암을 진단하기 위한 수단 및 방법 |
| CN105287473A (zh) | 2010-06-02 | 2016-02-03 | 扩散药品有限公司 | 包含双极性反式类胡萝卜素的组合物及其应用 |
| WO2017165667A1 (en) | 2016-03-24 | 2017-09-28 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer |
| KR102012554B1 (ko) * | 2016-07-13 | 2019-08-23 | 주식회사 노브메타파마 | 사이클로 히스티딘-프롤린을 유효성분으로 포함하는 세포 보호용 조성물 |
| CN114028388B (zh) * | 2021-12-16 | 2023-05-12 | 郑州大学第一附属医院 | 脯氨酸在制备肺癌治疗药物中的应用 |
| CN116092631A (zh) * | 2023-01-17 | 2023-05-09 | 湖南安泰康成生物科技有限公司 | 铁死亡诱导剂与电场联用的肿瘤治疗系统 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| CA1281288C (en) * | 1984-11-05 | 1991-03-12 | Wilhelm Hoerrmann | Tumor therapy |
| US6153643A (en) * | 1984-11-05 | 2000-11-28 | Hoerrmann; Wilhelm | Anti-cancer-substance |
| US5665371A (en) * | 1985-05-20 | 1997-09-09 | Hoerrmann; Wilhelm | Medicines which contain derivatives of proline or hydroxyproline |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5837283A (en) * | 1997-03-12 | 1998-11-17 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
| DE10359828A1 (de) | 2003-12-12 | 2005-07-28 | Zoser B. Dr.Rer.Nat. Salama | CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe |
| CA2548391A1 (en) | 2003-12-18 | 2005-06-30 | Zoser B. Salama | Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours |
-
2005
- 2005-06-07 WO PCT/EP2005/006184 patent/WO2005120495A1/en active Application Filing
- 2005-06-07 EP EP05770217A patent/EP1765328B1/en not_active Not-in-force
- 2005-06-07 AU AU2005251463A patent/AU2005251463A1/en not_active Abandoned
- 2005-06-07 AT AT05770217T patent/ATE534386T1/de active
- 2005-06-07 MX MXPA06014731A patent/MXPA06014731A/es not_active Application Discontinuation
- 2005-06-07 JP JP2007515831A patent/JP2008502622A/ja not_active Withdrawn
- 2005-06-07 CN CNA2005800238112A patent/CN1997365A/zh active Pending
- 2005-06-07 RU RU2007101074/15A patent/RU2007101074A/ru not_active Application Discontinuation
- 2005-06-07 ZA ZA200700367A patent/ZA200700367B/en unknown
- 2005-06-07 BR BRPI0512040-3A patent/BRPI0512040A/pt not_active IP Right Cessation
- 2005-06-07 CA CA002568306A patent/CA2568306A1/en not_active Abandoned
- 2005-06-07 KR KR1020067027243A patent/KR20070026646A/ko not_active Application Discontinuation
- 2005-06-08 US US11/147,648 patent/US7727530B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE534386T1 (de) | 2011-12-15 |
| EP1765328B1 (en) | 2011-11-23 |
| RU2007101074A (ru) | 2008-07-20 |
| CN1997365A (zh) | 2007-07-11 |
| US7727530B2 (en) | 2010-06-01 |
| WO2005120495A1 (en) | 2005-12-22 |
| US20050276810A1 (en) | 2005-12-15 |
| AU2005251463A1 (en) | 2005-12-22 |
| CA2568306A1 (en) | 2005-12-22 |
| EP1765328A1 (en) | 2007-03-28 |
| MXPA06014731A (es) | 2007-04-25 |
| KR20070026646A (ko) | 2007-03-08 |
| JP2008502622A (ja) | 2008-01-31 |
| ZA200700367B (en) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0512040A (pt) | composição farmacêutica, método de modificação de receptores de célula de tumor, método de aperfeiçoar seletividade alvo de anticorpos, método de tratar cáncer, kit, uso de prolina | |
| CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
| UY39024A (es) | Proteínas terapéuticas de unión a dll4 | |
| CY1119454T1 (el) | Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος | |
| MX2014000555A (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
| EA202091514A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR | |
| EA201100779A1 (ru) | Композиции антител к cxcr1 и способы их применения | |
| ECSP15005280A (es) | Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos | |
| CR9512A (es) | Metodos para el tratamiento de tumores de cerebro con anticuerpos | |
| SG170728A1 (en) | Anti-tumor cell antigen antibody therapeutics | |
| CY1115572T1 (el) | Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| EA201390328A1 (ru) | Новые антигенсвязывающие белки | |
| BR112012026213A2 (pt) | pirrolobenzodiazepinas e conjugados das mesmas | |
| BRPI0711908B8 (pt) | anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo. | |
| AR075896A1 (es) | Anticuerpos anti-her (factor de crecimiento epidermico) | |
| BRPI0618552B8 (pt) | compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos | |
| NO20091661L (no) | Anvendelse av pegylert IL-10 for a behandle kreft | |
| BRPI0613382A8 (pt) | anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor | |
| WO2010019702A3 (en) | Ddr1-binding agents and methods of use thereof | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| EA201591191A1 (ru) | Антитела против ntb-a и связанные с ними композиции и способы | |
| ES2723827T3 (es) | Terapia de combinación de fármacos para el tratamiento de tumores sólidos | |
| MX2020009842A (es) | Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido. | |
| BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |